This is a news story, published by Yahoo, that relates primarily to FDA news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
GIP receptor agonist. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest main active ingredient tirzepatide news, active ingredient tirzepatide news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weight lossGood Morning America
•83% Informative
Mounjaro, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight.
Ozempic, a medication approved by the FDA for Type 2 diabetes, lost more weight than those with diabetes.
The study analyzed more than 18,000 patients with obesity, both with and without diabetes.
VR Score
81
Informative language
79
Neutral language
52
Article tone
semi-formal
Language
English
Language complexity
59
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
9
Source diversity
3
Affiliate links
no affiliate links